Literature DB >> 21171080

Pro-inflammatory chemokine-chemokine receptor interactions within the Ewing sarcoma microenvironment determine CD8(+) T-lymphocyte infiltration and affect tumour progression.

Dagmar Berghuis1, Susy J Santos, Hans J Baelde, Antonie Hm Taminiau, R Maarten Egeler, Marco W Schilham, Pancras Cw Hogendoorn, Arjan C Lankester.   

Abstract

Ewing sarcoma is an aggressive round cell sarcoma with poor patient prognosis, particularly in cases of advanced-stage disease. Dynamic tumor-host immune interations within the tumor microenvironment may polarize in situ immune responses and shape tumor development and/or progression. To gain insight into the nature of tumour-host immune interactions within the Ewing sarcoma microenvironment, the presence and spatial distribution of infiltrating CD8(+) /CD4(+) T-lymphocytes were evaluated in therapy-naive Ewing sarcoma. Expression profiling of 40 different chemokines and several chemokine receptors was performed in therapy-naive tumours and cell lines by qPCR, immunohistochemistry, and flow cytometry. Considerable inter-tumour variation was observed regarding density, type, and distribution of infiltrating T-lymphocytes. Tumour-infiltrating T-cells contained significantly higher percentages of CD8(+) T-lymphocytes as compared to stroma-infiltrating cells, suggesting preferential migration of this T-cell type into tumour areas. Gene expression levels of several type 1-associated, pro-inflammatory chemokines (CXCR3- and CCR5-ligands CXCL9, CXCL10, and CCL5) correlated positively with infiltrating (CD8(+) ) T-lymphocyte numbers expressing corresponding chemokine receptors. Survival analyses demonstrated an impact of tumour-infiltrating, and not stroma-infiltrating, CD8(+) T-lymphocytes on tumour progression. At protein level, both tumour and stromal cells expressed the IFNγ-inducible chemokines CXCL9 and CXCL10. CCR5-ligand CCL5 was exclusively expressed by non-tumoural stromal/infiltrating cells. Together, our results indicate that an inflammatory immune microenvironment with high expression of type 1-associated chemokines may be critical for the recruitment of (CD8(+) ) T-lymphocytes expressing corresponding chemokine receptors. The observed impact of tumour-infiltrating (CD8(+) ) T-lymphocytes is consistent with a role for adaptive anti-tumour immunity in the prevention of Ewing sarcoma progression. Recognition of the merits and exploitation/induction of an inflammatory microenvironment may improve the efficacy of natural immune responses against, and (adoptive) immunotherapeutic approaches for, Ewing sarcoma.
Copyright © 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21171080     DOI: 10.1002/path.2819

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  60 in total

1.  Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood.

Authors:  Eric W Klee; Olga P Bondar; Marcia K Goodmanson; Roy B Dyer; Sibel Erdogan; Eric J Bergstralh; H Robert Bergen; Thomas J Sebo; George G Klee
Journal:  Clin Chem       Date:  2012-01-12       Impact factor: 8.327

Review 2.  Immunotherapeutic strategies for sarcoma: current perspectives.

Authors:  Xueyao Li; Gangyang Wang; Zhengdong Cai; Wei Sun
Journal:  Am J Transl Res       Date:  2020-12-15       Impact factor: 4.060

3.  The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting.

Authors:  Djordje Atanackovic; Henrike Reinhard; Sabrina Meyer; Stefanie Spöck; Tobias Grob; Tim Luetkens; Sara Yousef; Yanran Cao; York Hildebrandt; Julia Templin; Katrin Bartels; Nesrine Lajmi; Heribert Stoiber; Nicolaus Kröger; Judith Atz; Diane Seimetz; Jakob R Izbicki; Carsten Bokemeyer
Journal:  Hum Vaccin Immunother       Date:  2013-08-16       Impact factor: 3.452

Review 4.  Immunotherapy in Sarcoma: Future Horizons.

Authors:  Melissa Burgess; Vikram Gorantla; Kurt Weiss; Hussein Tawbi
Journal:  Curr Oncol Rep       Date:  2015-11       Impact factor: 5.075

5.  Immunohistochemical analysis and prognostic significance of PD-L1, PD-1, and CD8+ tumor-infiltrating lymphocytes in Ewing's sarcoma family of tumors (ESFT).

Authors:  Isidro Machado; Jose Antonio López-Guerrero; Katia Scotlandi; Piero Picci; Antonio Llombart-Bosch
Journal:  Virchows Arch       Date:  2018-02-14       Impact factor: 4.064

6.  GLI2 transcription factor mediates cytokine cross-talk in the tumor microenvironment.

Authors:  Sherine F Elsawa; Luciana L Almada; Steven C Ziesmer; Anne J Novak; Thomas E Witzig; Stephen M Ansell; Martin E Fernandez-Zapico
Journal:  J Biol Chem       Date:  2011-03-18       Impact factor: 5.157

Review 7.  Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.

Authors:  Michael J Nathenson; Anthony P Conley; Edward Sausville
Journal:  Oncologist       Date:  2017-09-21

Review 8.  Potential of human γδ T cells for immunotherapy of osteosarcoma.

Authors:  Zhaoxu Li
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

9.  Sarcoma Tumor Microenvironment.

Authors:  Panagiotis Tsagozis; Jordi Gonzalez-Molina; Anna-Maria Georgoudaki; Kaisa Lehti; Joseph Carlson; Andreas Lundqvist; Felix Haglund; Monika Ehnman
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

10.  Prognostic profiling of the immune cell microenvironment in Ewing´s Sarcoma Family of Tumors.

Authors:  David Stahl; Andrew J Gentles; Ralf Thiele; Ines Gütgemann
Journal:  Oncoimmunology       Date:  2019-10-13       Impact factor: 8.110

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.